<DOC>
	<DOCNO>NCT00602589</DOCNO>
	<brief_summary>The primary objective study assess bioequivalence oral suspension formulation , oral solution formulation , market tablet formulation levofloxacin , market tablet reference .</brief_summary>
	<brief_title>A Study Evaluate Bioequivalence Oral Suspension Formulation , Oral Solution Formulation , Marketed Tablet Formulation Levofloxacin Healthy Subjects</brief_title>
	<detailed_description>In single-dose study conduct single center , 3 oral formulation levofloxacin ( tablet , suspension , solution ) assess bioequivalence healthy men woman age 18 55 year old . Subjects assign different treatment base chance ; researcher study participant knew treatment administer . The study consist screening period , 3 open-label treatment period separate washout period least 4 day dos , post-treatment period . Subjects receive single dose 3 study formulation , administer single dose formulation Day 1 treatment period . Blood sample collect Days 1 , 2 , 3 treatment period immediately dose 0.25 , 0.5 , 0.75 , 1 , 1.5 , 2 , 4 , 6 , 10 , 14 , 24 , 30 , 36 , 48 hour dose measurement levofloxacin concentration . Subjects admit study site prior dose remain 48-hour measurement Day 3 . The post-treatment period include physical examination clinical laboratory test ensure subject safety discharge study . Safety evaluation , include adverse event monitoring , standard clinical laboratory evaluation ( hematology , serum chemistry , urinalysis ) , vital sign monitoring , physical examination , monitor throughout study . Two cohort 36 subject enrol study . The first cohort receive single dose study drug complete Period 1 ; study stop reinitiated . Subjects first cohort complete early termination procedure ; data include safety analysis , however , blood sample levofloxacin concentration analyze include pharmacokinetic analysis . Thirty-four subject second cohort complete study procedure . Levofloxacin oral suspension ( 125 mg/5 mL ) , levofloxacin oral solution ( 125 mg/5 mL ) , levofloxacin tablet ( 500 mg ) administer Day 1 treatment period .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Men woman Aged 18 55 year BMI 18 30 kg/m2 No prescription overthecounter medication previous 14 day Negative test drug alcohol abuse , HIV , hepatitis B hepatitis C Healthy base medical history , physical examination , 12lead electrocardiogram , toxicology , antigen , antibody screen , clinical laboratory evaluation Allergic reaction quinolones Clinically significant ECG clinical laboratory abnormality Creatinine clearance &lt; =80 mL/min Acute illness within 7 day Nicotine use within 1 year Receipt experimental drug device within 60 day Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>open-label</keyword>
	<keyword>randomize</keyword>
	<keyword>crossover</keyword>
	<keyword>bioequivalence</keyword>
</DOC>